Phosphodiesterase-3 inhibitor (cilostazol) attenuates oxidative stress-induced mitochondrial dysfunction in the heart

Journal of Geriatric Cardiology

Volumn 11, Issue 2, 2014, Pages 151-157

  Chattipakorn, Siriporn C ^a,b   Thummasorn, Savitree ^a   Sanit, Jantira ^a   Chattipakorn, Nipon ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Cilostazol; Heart; Ischemia; Membrane potential; Mitochondria; Oxidative stress; Phosphodiesterase 3 inhibitor

Indexed keywords

4' CHLORODIAZEPAM; CILOSTAZOL; CYCLOSPORIN A; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; HEART DEPOLARIZATION; HEART MITOCHONDRION; HEART PROTECTION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION SWELLING; NONHUMAN; OXIDATIVE STRESS; RAT;

EID: 84904509817     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1671-5411.2014.02.014     Document Type: Article

References (33)

1. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993; 329: 149-155. (Pubitemid 23195734)
2. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.
3. Atarashi H, Endoh Y, Saitoh H, et al. Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias. J Cardiovasc Pharmacol 1998; 31: 534-539. (Pubitemid 28153129)
4. Cone J, Wang S, Tandon N, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999; 34: 497-504. (Pubitemid 29446916)
5. Feldman AM, McNamara DM. Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease. Clin Cardiol 2002; 25: 256-262. (Pubitemid 34568582)
6. Gamssari F, Mahmood H, Ho JS, et al. Rapid ventricular tachycardias associated with cilostazol use. Tex Heart Inst J 2002; 29: 140-142. (Pubitemid 34627579)
7. Kambayashi J, Liu Y, Sun B, et al. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003; 9: 2289-2302. (Pubitemid 37236353)
8. Kishida M, Watanabe K, Tsuruoka T. [Effects of cilostazol in patients with bradycardiac atrial fibrillation]. J Cardiol 2001; 37: 27-33.
9. Kodama-Takahashi K, Kurata A, Ohshima K, et al. Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block. Chest 2003; 123: 1161-1169. (Pubitemid 36444374)
10. Toyonaga S, Nakatsu T, Murakami T, et al. Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia. J Cardiovasc Pharmacol Ther 2000; 5: 183-191. (Pubitemid 30483495)
11. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999; 100: 21-26. (Pubitemid 29297935)
12. Tsuchiya T. Role of pharmacotherapy in Brugada syndrome. Indian Pacing Electrophysiol J 2004; 4: 26-32. (Pubitemid 38964060)
13. Tsuji T, Ueda H, Nakatsu T, et al. Effects of cilostazol on heart rate and its variability in patients with sick sinus syndrome. Clin Drug Invest 2001; 21: 605-612. (Pubitemid 32937979)
14. Watanabe K, Ikeda S, Komatsu J, et al. Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. Am J Cardiol 2003; 92: 21-25. (Pubitemid 36782303)
15. Liu Y, Shakur Y, Yoshitake M, et al. Cilostazol (Pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001; 19: 369-386. (Pubitemid 34260705)
16. Wang S, Cone J, Fong M, et al. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 2001; 38: 775-783. (Pubitemid 32983284)
17. Tsuchiya T, Ashikaga K, Honda T, et al. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002; 13: 698-701. (Pubitemid 34774909)
18. Kanlop N, Shinlapawittayatorn K, Sungnoon R, et al. Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine. Can J Physiol Pharmacol 2010; 88: 422-428.
19. Cortassa S, Aon MA, Winslow RL, O'Rourke B. A mitochondrial oscillator dependent on reactive oxygen species. Biophys J 2004; 87: 2060-2073. (Pubitemid 39167059)
20. Thummasorn S, Kumfu S, Chattipakorn S, et al. Granulocyte-colony stimulating factor attenuates mitochondrial dysfunction induced by oxidative stress in cardiac mitochondria. Mitochondrion 2011; 11: 457-466.
21. Aon MA, Cortassa S, Marban E, et al. Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. J Biol Chem 2003; 278: 44735-44744. (Pubitemid 37377231)
22. Brady NR, Hamacher-Brady A, Westerhoff HV, et al. A wave of reactive oxygen species (ROS)-induced ROS release in a sea of excitable mitochondria. Antioxid Redox Signal 2006; 8: 1651-1665. (Pubitemid 44726339)
23. Chen Q, Moghaddas S, Hoppel CL, et al. Ischemic defects in the electron transport chain increase the production of reactive oxygen species from isolated rat heart mitochondria. Am J Physiol Cell Physiol 2008; 294: C460-C466. (Pubitemid 351276913)
24. Walker JM. The bicinchoninic acid (BCA) assay for protein quantitation. Methods Mol Biol 1994; 32: 5-8.
25. 2+ uptake during simulated ischemia does not affect permeability transition pore opening upon simulated reperfusion. Cardiovasc Res 2006; 71: 715-724.
26. Novalija E, Kevin LG, Eells JT, et al. Anesthetic preconditioning improves adenosine triphosphate synthesis and reduces reactive oxygen species formation in mitochondria after ischemia by a redox dependent mechanism. Anesthesiology 2003; 98: 1155-1163. (Pubitemid 36520202)
27. Di Lisa F, Blank PS, Colonna R, et al. Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition. J Physiol 1995; 486 (Pt 1): 1-13.
28. Tong V, Teng XW, Chang TK, et al. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci 2005; 86: 436-443. (Pubitemid 41418656)
29. Kanlop N, Chattipakorn S, Chattipakorn N. Effects of cilostazol in the heart. J Cardiovasc Med (Hagerstown) 2011; 12: 88-95.
30. Petronilli V, Penzo D, Scorrano L, et al. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J Biol Chem 2001; 276: 12030-12034.
31. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995; 1241: 139-176.
32. Rao YJ, Xi L. Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol Sin 2009; 30: 1-24.
33. Fukasawa M, Nishida H, Sato T, et al. 6-[4-(1-Cyclohexyl-1H-tetrazol-5- yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts. J Pharmacol Exp Ther 2008; 326: 100-104. (Pubitemid 351872116)